Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2264-2025

UIBC (Unsaturated Iron Binding Capacity), REF: OSR61205 Recall

UIBC (Unsaturated Iron Binding Capacity), REF: OSR61205,

FDA recall Class II

Ongoing

FDA lists this Class II recall for UIBC (Unsaturated Iron Binding Capacity), REF: OSR61205. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2264-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jun 26, 2025
FDA report date
Aug 13, 2025
Quantity in commerce
56,696 units
Distribution
See key details
FDA cause
Process design

What is being recalled?

UIBC (Unsaturated Iron Binding Capacity), REF: OSR61205,

Affected model & UDI checker

Search the exact identifiers published for Z-2264-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
OSR61205UIBC (Unsaturated Iron Binding Capacity), REF: OSR61205Check source noticeNot specified
FDA code information

All Lots/(01)15099590011925

View the original FDA recall notice

Why was this product recalled?

Beckman Coulter identified that the Unsaturated Iron Binding Capacity (UIBC) assay is not meeting their labeled hemoglobin interference claims of no significant interference (i.e., less than 10%) up to 200 mg/dL hemoglobin as indicated in their instructions for use. Initial internal testing confirmed that samples with low UIBC levels failed the claimed hemolysis interference specifications with reported biases up to -43.6 % UIBC when hemolyzed serum samples contained 200 mg/dL hemoglobin.

What actions did BECKMAN COULTER, INC. take?

On July 10, 2025, Beckman Coulter issued a "Urgent Medical Device Recall" via mail and E-Mail to affected consignees. Beckman Coulter asked consignees to take the following action: 1. Sharing the content of this letter with your laboratory and/or Medical Director to evaluate the requirement for a retrospective review of UIBC results for hemolysed samples. 2. Discontinuance or disposal of this product is not necessary. 3. Per the IFU, avoid hemolysed samples when using the UIBC assay. 4. If the LIH influence check setting for hemolysis has been enabled on AU/DxC AU instruments for UIBC, update the setting per the instructions in the letter. 5. Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. 6. If you have forwarded any of the affected product listed above to another laboratory, please provide them a copy of this letter. 7. So that we are assured you have received this important communication, please respond within 10 days in one of the following ways: Electronically, if you received this communication via email or manually, complete and return the enclosed Response Form.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology